Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
8
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[THE INVESTOR] Total accumulated exports of Celltrion’s Remsima, a biosimilar version of Johnson & Johnson’s Remicade, have exceeded 1 trillion won (US$890 million), the South Korean drug maker’s overseas marketing affiliate Celltrion Healthcare said on Oct. 19.
It took four years for Celltrion to reach the figure since the pharmaceutical firm shipped the first batch of its rheumatoid arthritis treatment drug Remsima in 2012.
“The exports of Remsima are expected to rise at a faster clip if the drug hits the US pharmacy shelves in November,” an official at the firm said.
It took four years for Celltrion to reach the figure since the pharmaceutical firm shipped the first batch of its rheumatoid arthritis treatment drug Remsima in 2012.
“The exports of Remsima are expected to rise at a faster clip if the drug hits the US pharmacy shelves in November,” an official at the firm said.
Starting with only 800 billion won worth of exports in 2012, the figure surged to 494.4 billion won in 2015, according to the company.
So far, Remsima has been sold in mainly European countries including Hungary and Croatia as well as Japan.
The cheaper copycat version will compete with original drug Remicade from November in the US market as it received the greenlight for sale from the Food and Drug Administration in April.
By Park Han-na (hnpark@heraldcorp.com)
